MAOYAN ENT Surges Over 3% in Morning Session as Citi Maintains "Buy" Rating

Deep News
11/11

MAOYAN ENT (01896) rose more than 7% intraday during the trading session. As of press time, the stock was up 3.44% at HK$7.81, with a turnover of HK$121 million.

Recently, Citi issued a report initiating a 30-day positive catalyst watch on MAOYAN ENT, citing the upcoming release of the major animated film *Demon Slayer: Kimetsu no Yaiba* on November 14, for which MAOYAN serves as the distributor. The film has already demonstrated strong global box office performance, ranking fifth worldwide with over $677 million in revenue and becoming the top international film in North America. The announcement has generated significant buzz, evidenced by a record-breaking 400,000 "want-to-watch" clicks on MAOYAN's professional platform within a single day.

Citi expects *Demon Slayer* to become the highest-grossing Japanese animated film in China, projecting box office revenue of up to RMB 1 billion. The bank estimates a potential profit contribution ranging between RMB 108 million and RMB 200 million. Citi also anticipates that any outperformance in box office results could serve as a positive catalyst for MAOYAN as the largest ticketing platform. The bank maintains a "Buy" rating with a target price of HK$9.3, based on a 14x adjusted 2026 earnings multiple.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10